Joint (JYNT) Stock Price, News & Analysis

Company Overview

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Key Stats

• Today's Range: $11.35 to $11.53
• 50-Day Range: $9.90 to $11.72
• 52-Week Range: $9.10 to $17.82
• Volume: 49,309 shs
• Average Volume: 26,290 shs
• Market Capitalization: $170.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Buy

Joint Stock Analysis - MarketRank™

Joint scored higher than 81% of companies evaluated by MarketBeat, and ranked 207th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Joint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Joint has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 381.82%

Earnings Growth

Earnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.

Price to Book Value per Share Ratio

Joint has a P/B Ratio of 6.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.91% of the outstanding shares of Joint have been sold short.

Short Interest Ratio / Days to Cover

Joint has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Joint has recently decreased by 9.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Joint does not currently pay a dividend.

Dividend Growth

Joint does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.91% of the outstanding shares of Joint have been sold short.

Short Interest Ratio / Days to Cover

Joint has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Joint has recently decreased by 9.46%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.98

News Sentiment

Joint has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Joint this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Joint insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.20% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JYNT Stock Analysis - Frequently Asked Questions

How have JYNT shares performed this year?

Joint's stock was trading at $10.63 on January 1st, 2025. Since then, JYNT stock has increased by 6.8% and is now trading at $11.35.
View the best growth stocks for 2025 here.

How were Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) announced its quarterly earnings results on Wednesday, September, 13th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by $0.02. The company had revenue of $29.31 million for the quarter, compared to analysts' expectations of $29.85 million. Joint had a positive trailing twelve-month return on equity of 8.24% and a negative net margin of 13.95%.

When did Joint IPO?

Joint (JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

Who are Joint's major shareholders?

Top institutional shareholders of Joint include Skylands Capital LLC (4.93%), Renaissance Technologies LLC (2.18%), Topline Capital Management LLC (2.17%) and Clayton Partners LLC (2.07%). Insiders that own company stock include Bandera Partners Llc, Peter D Holt and Jake Singleton.
View institutional ownership trends.

How do I buy shares of Joint?

Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 9/13/2023
• Today: 2/22/2025
• Next Earnings (Estimated): 4/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Patent owners & lessors
• Sub-Industry: Trading
• Current Symbol: NASDAQ:JYNT
• CUSIP: N/A
• CIK: 1612630
• Web: www.thejoint.com
• Phone: (480) 245-5960
• Fax: 480-513-7989
• Employees: 320
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +54.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 103.18
• P/E Growth: N/A
• Net Income: $-9,750,000.00
• Net Margins: -13.95%
• Pretax Margin: -4.59%
• Return on Equity: 8.24%
• Return on Assets: 2.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $117.70 million
• Price / Sales: 1.44
• Cash Flow: $0.73 per share
• Price / Cash Flow: 15.65
• Book Value: $1.68 per share
• Price / Book: 6.76

Miscellaneous

• Outstanding Shares: 14,980,000
• Free Float: 10,459,000
• Market Cap: $170.02 million
• Optionable: Optionable
• Beta: 1.60